ArticlePediatric blood & cancer2026
Venous Thromboembolism in Pediatric Bone Sarcoma Patients: A 10-Year, Single-Institution Experience Encompassing the COVID-19 Pandemic.
Article in Pediatric blood & cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundOsteosarcoma (OS) and Ewing sarcoma (EWS) are the most common primary bone cancers in children, but acute thrombosis is poorly characterized in this population. Our study evaluated the rates of venous thromboembolism (VTE) and associated risk factors in pediatric patients with bone sarcomas treated over a 10-year period encompassing the emergence of COVID-19. PROCEDURE: Data were obtained via EMR review for patients diagnosed with OS and EWS at Texas Children's Hospital from 2014 to 2023. Statistical analyses were performed using Fisher's exact, chi-square, and Wilcoxon rank-sum tests. Change in VTE rate prior to and after 2020 was compared using interrupted time series analysis.
resultsAmong 137 eligible patients, the majority were diagnosed with OS (n = 85, 62%) compared to EWS (n = 52, 38%). Twelve patients (8.8%) developed VTEs during primary cancer therapy. Femoral tumor location was associated with increased VTE occurrence (p = 0.016), and there was a trend toward increased VTE in OS (p = 0.13) and obese patients (p = 0.2). VTE rates increased after the emergence of COVID-19, although only one affected patient tested positive. The incidence rate ratio pre- and post-COVID-19 emergence (2014-2019 vs. 2020-2023) was 8.7 (95% CI: 2.29-56.61; p = 0.005). This increase in VTEs after 2020 was sustained.
conclusionOur cohort represents the largest population of pediatric patients with bone sarcomas studied to date. In our 10-year analysis, we observed a sustained increase in VTE events following the emergence of COVID-19. Additionally, our data suggest that subsets of this patient population, specifically obese patients with OS and femoral tumors, should be closely monitored for thrombosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.